10 DexCom Analyst Ratings, Earnings, Dividends and Insider Trades | $DXCM | NYSE:DXCM | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact DexCom Company Profile (NYSE:DXCM) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for DexCom (NYSE:DXCM) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 5 Buy Rating(s)Consensus Rating:Hold (Score: 2.44)Consensus Price Target: $32.58 31.29% downside) Analysts' Ratings History for DexCom (NYSE:DXCM) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare1/24/2014Canaccord GenuityBoost Price TargetBuy$34.00 -> $44.00View 1/14/2014Benchmark Co.Boost Price Target$44.00View 11/7/2013WedbushBoost Price TargetOutperform$39.00View 11/7/2013Raymond JamesBoost Price TargetOutperform$31.00 -> $34.00View 11/7/2013Northland Capital PartnersUpgradeMarket PerformView 11/7/2013Jefferies GroupBoost Price TargetBuy$27.00 -> $40.00View 11/7/2013Canaccord GenuityBoost Price TargetBuy$26.00 -> $34.00View 11/7/2013Benchmark Co.Boost Price TargetBuy$37.00 -> $40.00View 10/15/2013Benchmark Co.Initiated CoverageBuy$37.00View 10/14/2013Raymond JamesBoost Price TargetOutperform$26.00 -> $31.00View 9/13/2013JPMorgan Chase & Co.Initiated CoverageOverweight$32.00View 8/13/2013WedbushBoost Price TargetOutperform$18.00 -> $31.00View 8/12/2013Feltl & Co.Boost Price TargetSell$16.50 -> $18.25View 8/8/2013Jefferies GroupBoost Price TargetBuy$21.00 -> $27.00View 8/8/2013Canaccord GenuityBoost Price TargetBuy$25.00 -> $26.00View 7/25/2013Northland Capital PartnersBoost Price TargetMarket Perform -> Underperform$15.00 -> $17.00View 6/25/2013Raymond JamesBoost Price TargetOutperform$20.00 -> $23.00View 6/24/2013Canaccord GenuityBoost Price TargetBuy$19.00 -> $25.00View 6/20/2013Leerink SwannBoost Price TargetMarket Perform$17.00 -> $22.00View 6/13/2013Feltl & Co.DowngradeHold -> SellView 6/10/2013WunderlichDowngradeBuy -> Hold$20.00View 5/6/2013Jefferies GroupBoost Price Target$16.50 -> $21.00View 5/2/2013WedbushBoost Price TargetOutperform$17.00 -> $18.00View 5/2/2013Northland Capital PartnersBoost Price Target$12.00 -> $15.00View 5/2/2013Leerink SwannBoost Price TargetMarket Perform$14.50 -> $17.00View 4/29/2013Raymond JamesBoost Price TargetOutperform$17.00 -> $18.00View (Data available from 3/8/2012 forward) Earnings History for DexCom (NYSE:DXCM)No earnings announcements for this company have been tracked by Analyst Ratings Network Dividend History for DexCom (NYSE:DXCM)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for DexCom (NYSE:DXCM)No insider trades for this company have been tracked by Analyst Ratings Network About DexCom DexCom, Inc. is a medical device company. The Company focuses on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. On February 13, 2009, the Company received approval for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. On October 30, 2009, the Company received Conformit Europeene (CE) Mark approval for its blood-based, in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. Headlines: (3/5) Dexcom Supports NASCAR Driver Ryan Reed’s American Diabetes Association Drive to Stop Diabetes℠ Initiative (3/4) Is DexCom (DXCM) a Great Growth Stock? (2/25) DexCom Beats, Sees Narrower Q4 Loss (2/14) Can the Rally in DexCom (DXCM) Shares Continue? (2/25) DexCom Announces Upcoming Conference Presentations (2/20) DexCom, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results (2/6) FDA Approval for DexCom's G4 PLATINUM (2/14) Can the Rally in DexCom (DXCM) Shares Continue? - Tale of the Tape Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NYSE Symbol: DXCM CUSIP: Key Metrics: Previous Close: $47.5450 Day Moving Average: $41.6282200 Day Moving Average: $33.5892 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $3.453BCurrent Quarter EPS Consensus Estimate: $-0.09 EPS Additional Links: View DXCM on Google FinanceView DXCM on Yahoo FinanceView DXCM's Company Profile on ReutersSearch for DexCom on Google DexCom (NYSE:DXCM) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.